Reduced phosphatases and hyperphosphorylated glutamatergic receptors persist from early to late stages of prion disease
- 1Department of Pathology, University of California at San Diego
Abstract
Synapse loss occurs early in prion disease, yet the intracellular signaling driving this dysregulation remains poorly understood. Evidence of neuronal hyperactivity was reported in humans with sporadic and familial CJD as well as in the early stages of prion disease in mice (strain 22L). Here we perform a longitudinal study of prion-infected mice (strain RML) and show an increase in the immediate-early gene, Arc, suggesting this is a conserved response to prions. We also observed a persistent decrease in phosphatase abundance (PP1 and PP2B) starting at the earliest timepoint (preclinical) in the cerebral cortex. At this stage, mGluR5 dimers and phosphorylated AMPA receptors were increased. By clinical disease onset, mGluR5 dimers declined, and activity shifted toward NMDA receptor activation, marked by GluN2B hyperphosphorylation. Together, these findings suggest that early phosphatase reduction accompanies neuronal hyperactivity and precedes substantial inflammation. Elucidating the mechanisms driving this early phosphatase loss and its role in neuronal hyperactivity may reveal novel therapeutic targets for prion disease.
Related
- Protein Tyrosine Phosphatases in Cancer: From Oncogenic Drivers to Therapeutic Targets
- A family of metabolite damage-control phosphatases modulates ROS-induced autophagy and plant stress resilience
- Cdc14 and PP2A Phosphatases Cooperate to Shape Phosphoproteome Dynamics during Mitotic Exit
- PepRePs: Peptide-Retargeted Phosphatases Designed with Generative Language Models
- From Metabolite to Signalling: Evolutionary Assembly of the Glutamatergic System Across Metazoans
BibTeX
@misc{rajic2026reduced,
title = {{Reduced phosphatases and hyperphosphorylated glutamatergic receptors persist from early to late stages of prion disease}},
author = {A. J. Rajic and D. Ojeda-Juarez and D. Sarkar and P. Sumowski and S. Flores and M. Pourhamzeh and K. Soldau and D. P. Pizzo and C. J. Sigurdson},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.14.751571},
url = {https://www.biorxiv.org/content/10.64898/2026.10.14.751571v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Reduced phosphatases and hyperphosphorylated glutamatergic receptors persist from early to late stages of prion disease
AU - A. J. Rajic
AU - D. Ojeda-Juarez
AU - D. Sarkar
AU - P. Sumowski
AU - S. Flores
AU - M. Pourhamzeh
AU - K. Soldau
AU - D. P. Pizzo
AU - C. J. Sigurdson
PY - 2026
DA - 2026/10/14
PB - bioRxiv
DO - 10.64898/2026.10.14.751571
UR - https://www.biorxiv.org/content/10.64898/2026.10.14.751571v1
AB - Synapse loss occurs early in prion disease, yet the intracellular signaling driving this dysregulation remains poorly understood. Evidence of neuronal hyperactivity was reported in humans with sporadic and familial CJD as well as in the early stages of prion disease in mice (strain 22L). Here we perform a longitudinal study of prion-infected mice (strain RML) and show an increase in the immediate-early gene, Arc, suggesting this is a conserved response to prions. We also observed a persistent decrease in phosphatase abundance (PP1 and PP2B) starting at the earliest timepoint (preclinical) in the cerebral cortex. At this stage, mGluR5 dimers and phosphorylated AMPA receptors were increased. By clinical disease onset, mGluR5 dimers declined, and activity shifted toward NMDA receptor activation, marked by GluN2B hyperphosphorylation. Together, these findings suggest that early phosphatase reduction accompanies neuronal hyperactivity and precedes substantial inflammation. Elucidating the mechanisms driving this early phosphatase loss and its role in neuronal hyperactivity may reveal novel therapeutic targets for prion disease.
ER -